Matthew A. Summers

Matthew A. Summers

Auto-generated profile, based on publicly available information

Matthew A. Summers

Garvan Institute of Medical Research, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2020 in Expert Systems with Applications
Verified
Journal Article
Closed access
MAMartuza Ahamad
Martuza Ahamad
SASakifa Aktar
Sakifa Aktar
RMRashed- Al- Mahfuz
Rashed- Al- Mahfuz
Shahadat UddinShahadat Uddin
Shahadat Uddin
PLPietro Liò
Pietro Liò
MMMohammad Ali Moni
Mohammad Ali Moni

23 September 2019 in Cold Spring Harbor Perspectives in Medicine
Verified
Journal Article
Closed access
PDF file
MSMatthew A. Summers
Matthew A. Summers
MMMichelle M. McDonald
Michelle M. McDonald
PCPeter I. Croucher
Peter I. Croucher
Recurrent metastasis following extended periods of disease-free survival remains a common cause of morbidity and mortality for many cancer patients. Recurrence is thought to be mediated by tumor cells that escaped the primary site early in the disease course and colonize distant organs. In these locations, cells adapt to the local environment, entering a state of long-term dormancy in which they can resist therapy. Then, through mechanisms that are poorly understood, a proportion of these cells are reactivated and become proliferative, forming lethal metastases. Here, we discuss disseminated tumor cell dormancy in recurrent metastasis. We discuss mechanisms known to control entrance of cells into dormancy, highlighting the relevant microenvironments or “niches” in which these cells reside and mechanisms known to be involved in dormant cell reactivation. Finally, we consider emerging therapeutic approaches aimed at eradicating residual disease and preventing metastatic relapse.

1 January 2020 in Experimental Gerontology
Verified
Journal Article
Closed access
ASAhmed Al Saedi
Ahmed Al Saedi
SSShilpa Sharma
Shilpa Sharma
MSMatthew A. Summers
Matthew A. Summers
KNKulmira Nurgali
Kulmira Nurgali
Gustavo DuqueGustavo Duque
Gustavo Duque

11 August 2020 in Briefings in Bioinformatics
Verified
Journal Article
Closed access
ZNZulkar Nain
Zulkar Nain
Hunayan Kabir RanaHunayan Kabir Rana
Hunayan Kabir Rana
PLPietro Lio
Pietro Lio
Sheikh Mohammed Shariful IslamSheikh Mohammed Shariful Islam
Sheikh Mohammed Shariful Islam
MSMatthew A Summers
Matthew A Summers
MMMohammad Ali Moni
Mohammad Ali Moni
The novel coronavirus (2019-nCoV) has recently emerged, causing COVID-19 outbreaks and significant societal/global disruption. Importantly, COVID-19 infection resembles SARS-like complications. However, the lack of knowledge about the underlying genetic mechanisms of COVID-19 warrants the development of prospective control measures. In this study, we employed whole-genome alignment and digital DNA–DNA hybridization analyses to assess genomic linkage between 2019-nCoV and other coronaviruses. To understand the pathogenetic behavior of 2019-nCoV, we compared gene expression datasets of viral infections closest to 2019-nCoV with four COVID-19 clinical presentations followed by functional enrichment of shared dysregulated genes. Potential chemical antagonists were also identified using protein–chemical interaction analysis. Based on phylogram analysis, the 2019-nCoV was found genetically closest to SARS-CoVs. In addition, we identified 562 upregulated and 738 downregulated genes (adj. P ≤ 0.05) with SARS-CoV infection. Among the dysregulated genes, SARS-CoV shared ≤19 upregulated and ≤22 downregulated genes with each of different COVID-19 complications. Notably, upregulation of BCL6 and PFKFB3 genes was common to SARS-CoV, pneumonia and severe acute respiratory syndrome, while they shared CRIP2, NSG1 and TNFRSF21 genes in downregulation. Besides, 14 genes were common to different SARS-CoV comorbidities that might influence COVID-19 disease. We also observed similarities in pathways that can lead to COVID-19 and SARS-CoV diseases. Finally, protein–chemical interactions suggest cyclosporine, resveratrol and quercetin as promising drug candidates against COVID-19 as well as other SARS-like viral infections. The pathogenetic analyses, along with identified biomarkers, signaling pathways and chemical antagonists, could prove useful for novel drug development in the fight against the current global 2019-nCoV pandemic.

3 December 2018 in JBMR Plus
Verified
Journal Article
Open access
PDF file
Niall ByrneNiall Byrne
Niall Byrne
MSMatthew A Summers
Matthew A Summers
MMMichelle M McDonald
Michelle M McDonald
In the advanced stages of many cancers, tumor cells disseminate from the primary site and colonize distant locations such as the skeleton. These disseminated tumor cells colonizing bone can evade treatments and survive for prolonged periods in a dormant state before becoming reactivated to form overt metastases. The precise interactions between tumor cells and the bone microenvironment that promote survival, dormancy, and reactivation are currently unknown; as a result, bone metastases remain incurable. In this review we discuss the unique cellular and microenvironmental features of endosteal bone that tumor cells engage with to persist and survive, and ultimately reactivate and proliferate. Specifically, we provide a detailed summary of current perspectives on the processes of tumor cell colonization of the skeleton, and the endosteal bone cells as critical controllers of the dormant cancer cell phenotype, as well as relevant microenvironmental effects such as hypoxia. Evidence for the role of the osteoclast in controlling dormant cancer cell reactivation in bone is highlighted, preceding a discussion of therapeutics targeting the bone microenvironment, including anti‐RANK ligand and bisphosphonate therapies and their potential utility in preventing tumor cell reactivation in addition to protecting bone from tumor‐induced destruction. © 2018 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

9 August 2018 in Progress in Lipid Research
Verified
Journal Article
Closed access
EVEmily R. Vasiljevski
Emily R. Vasiljevski
MSMatthew A. Summers
Matthew A. Summers
DLDavid G. Little
David G. Little
ASAaron Schindeler
Aaron Schindeler